Founded in 2007, Nanexa has evolved from a materials science innovator into a clinical-stage pharmaceutical company. Today, PharmaShell® has demonstrated controlled release in clinical studies and progressed from laboratory development to in-house GMP manufacturing of investigational medicines at our pilot facility in Uppsala.
We continue to expand the platform across different drug types, advance new long-acting formulations and strengthen the development and manufacturing capabilities needed to make treatment simpler and more convenient.
- Anders Johansson, Nanexa’s co-founder and Head of Intellectual Property, on Nanexa’s origins and development.
